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CHRONICLES OF MEDICAL HISTORY
The Early Years of Clinical Pharmacokinetics
(1910 – 1976)
Science is largely close and reproducible examination
of relationships between physical phenomena. It was
by looking at the relationship between electricity and
magnetism and the relativity of their effects that
scientists created a whole revolution in scientific
thinking, leading from Michael Faraday to Albert
Einstein. The relationship between phenomena and time
has a very long history. The word ‘kinetic’ refers to
movement, displacement, usually in relation to time
or space.
About seven decades ago, pharmacologists started
examining the relationship between administered drugs,
blood or plasma concentrations, and time. Friedrich
Hartmut Dost (1910 – 1985) first introduced the word
pharmacokinetics in 1953; however, some of  the
subject matter has already been published.1 Dost was
a German pediatrician who used mathematical
calculations to optimize drug doses in children. The
purpose of  pharmacokinetics is to study the time
course of drug and metabolite concentrations or
amounts in biological fluids, tissues and excreta, and
of  pharmacological response, and to construct suitable
models to interpret such data. In pharmacokinetics,
data are analyzed using a mathematical representation
of a part or the whole of an organism. His studies
opened a new way of thinking of drug concentrations
and optimization of therapies in every aspect of clinical
pharmacology. In remembrance of  him, the German
Society for Clinical Pharmacology hosts an annual
award, the Friedrich-Hartmut-Dost Memorial Prize,
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SUMMARY
The German Friedrich Hartmut Dost (1910 – 1985) introduced the word
Pharmacokinetics. Clinical pharmacokinetics is the direct application of
knowledge regarding a drug’s pharmacokinetics to a therapeutic situation
in an individual or a population. It is the basis of therapeutic drug
monitoring with the ultimate goal of keeping drugs safe. This branch of
pharmacology has become the most relevant to the sub-specialty of  clinical
pharmacology. First reports of  Clinical Pharmacokinetics in Nigeria can
be credited to two gifted Nigerians, Prof Ayodele O. Iyun and Prof Lateef
A. Salako, both of whom were affiliated to the great institutions- University
of  Ibadan (UI) and the Teaching Hospital, University College Hospital
(UCH). Prof A.O Iyun was Nigeria’s first home-trained Clinical
Pharmacologist, while Prof  L.A. Salako played a most significant role in
the creation of  the Department of  Clinical Pharmacology, UCH.  This
edition of the Chronicles highlights a few of the first reports of this
exciting branch of  pharmacology in Nigeria. This historical review is
based on publications listed on the United States National Library of
Medicine database (PUBMED).
Clinical pharmacokinetics is the most important subject
in the curriculum of  Clinical Pharmacology. It is the
direct application of knowledge regarding the
pharmacokinetics of  a drug to a therapeutic situation
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in an individual or a population. It is the basis of
therapeutic drug monitoring with the ultimate goal of
keeping drugs safe. Initial studies of the subject were
published in journals of  physiology and biochemistry.
From Germany, in 1913, Michaelis and Menten
published what is now known as the Michaelis-Menten
equation for describing enzyme kinetics. In
pharmacokinetics, this same equation is used to
describe the elimination kinetics of ethanol, salicylate,
phenytoin and several other drugs.2 Other early
workers who moved the field forward were the
Swedish investigators Widmark and Tandberg (1924),
and the American Haggard (1924). Moller, Jolliffe,
Smith, and Hamilton introduced the concept of renal
clearance and basic mathematical equations relevant
to the field (1929 – 1935). Clinical pharmacokinetics
was fully established in the period between 1929 –
1950. In 1976, the journal Clinical Pharmacokinetics was
founded. The first studies of  Clinical Pharmacokinetics
in Nigeria were due largely to two gifted medical
doctors; Prof. Ayodele Oluremi Iyun and Prof Lateef
A. Salako.
Prof Ayodele Oluremi Iyun (1976 – 1989)
Prof Iyun was born in Lagos on 20 March 1944. He
attended Princess School, St. David School and Lagos
Government School before proceeding to King’s
college, Lagos from 1957 – 1961. He undertook
Higher School Certificate course at Federal School of
Science, Onikan, Lagos from 1963 – 1964. All through
his career, he excelled in all the courses he took. He
was admitted into the University of Ibadan in 1965
where he obtained the MBBS degree in June 1970. He
was the first UCH resident doctor to obtain both the
Master of  Medicine degree and the Nigerian Fellowship
in Physic (FMCP) in June 1977. In November 1978,
he was awarded the Fellowship of  the West African
College of  Physicians. His highly distinguished career
was full of many firsts; he started research that can be
considered today as the first reports of Clinical
Pharmacokinetics in Nigeria.
In 1979, Prof Iyun defended his thesis for the FMCP
fellowship titled Pharmacokinetic Studies in Hypertensive
Patients. This was followed by a brilliant career with
the University of Ibadan and University College
Hospital, Ibadan, where he went on to make significant
contributions to Clinical Pharmacokinetics. In 1982,
Iyun and Tucker described Antipyrine kinetics in
Nigerian women in chronic renal failure. He found
that the mean plasma antipyrine half-life in patients
with chronic renal failure was significantly shorter than
in normal subjects. The results suggested that oxidation
of antipyrine by hepatic microsomal enzymes is
increased in patients with chronic renal failure.3 By
measuring plasma metoprolol concentration, Iyun and
colleagues in 1986 described the role of genetic
polymorphism in the oxidative metabolism of
metoprolol and debrisoquin. He concluded that in
ethnic studies of drug metabolism each racial group
should be examined separately for evidence of
polymorphic metabolism and antimodes should not
be extrapolated from one population to another.4
Prof. AO Iyun
In 1988, Iyun and colleagues evaluated the
pharmacokinetics of  digoxin in eight healthy
volunteers, 23 congestive cardiac failure, and 10 chronic
renal failure patients. They found that the mean serum
digoxin concentrations in the volunteers and the
congestive cardiac failure patients were significantly
different from those in the chronic renal failure patients.
They also found that the mean half-life of digoxin in
the healthy volunteers (37.2 h +/- 8.6 s.d.) was
comparable to the widely accepted 40 h for digoxin
half-life in normal individuals. He recommended that
in the absence of  renal impairment and hypokalaemia,
standard dosages of digoxin could be used in
congestive cardiac failure patients, provided symptoms
and signs of toxicity are constantly monitored. Iyun
also recommended that therapeutic drug monitoring
of digoxin is desirable in view of its low toxicity:
therapeutic ratio, and its kinetics should be studied in
detail in each community to establish correct dosages
to prevent and manage digoxin toxicity.5
Nadolol is a non-selective beta-blocker used in the
treatment of  hypertension and long-term management
of  angina pectoris. The drug is 30% bound to protein
and has a half-life of  14 – 24 hours. Side effects include
dizziness and fatigue. In 1989, Prof Iyun and colleagues
reported clinical experience with nadolol in Nigerian
patients with essential hypertension.6 Although the study
did not report measurement of Nadolol
concentrations over time, Iyun closely observed
changes in cardiovascular parameters over time. He
discovered that Nadolol was highly effective in 15
patients (65.2%) moderately effective in 6 patients
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(26%) and ineffective in 2 patients (8.6%). He also stated
that side effects were not a problem in this study and
tolerance to the drug was excellent in most cases. At
about this time Prof Iyun had started collaborating
with another brilliant medical scientist, Prof Lateef A.
Salako.
Prof Lateef Akinola Salako (the period 1979 –
1994)
Prof Salako was born on 5 July 1935 at Otta, Ogun
State. Born to humble parents he rose to become one
of  the most formidable Pharmacologists Nigeria has
ever had. He received his education at St. James
Anglican School, Otta 1940 – 1947, Methodist Boys’
High School, Lagos 1948 – 1953, University of Ibadan
Medical School 1954 – 1961, and obtained the MBBS
degree of the University of London in 1961. In 1964,
he was awarded the MRCP, London, and went on to
obtain a Ph.D degree, Sheffield, in 1964. He was
appointed Consultant Clinical Pharmacologist,
University College Hospital, Ibadan in 1970 and he
became a Professor of  Pharmacology in 1974. His
Ph.D thesis was titled Studies on the Mechanism of Action
of Diuretics ‘in vitro’. 7
and pindolol in hypertensive Africans. Salako and
colleagues found that Pindolol diminished systolic
blood pressure at rest and after exercise and
antagonized exercise-induced tachycardia, but had no
effect on resting heart rate and that Propranolol
diminished systolic blood pressure predominantly after
exercise and reduced both resting and exercise heart
rate. Both drugs had no effect on diastolic pressure.
In 1971 Salako had written a paper on oral thiazide
diuretics in the treatment of hypertension in Nigeria,
describing his findings.12 He would go on to build a
very illustrious career in the study of anti-hypertensive
medications in Nigerians. During the period spanning
1983 – 1987, Prof Salako published six significant
papers on the pharmacokinetics of  chloroquine and
amodiaquine, the most widely used antimalarials at that
time.13-18 He found that with each route of
administration of chloroquine the area under the plasma
concentration-time curve was less than that for whole
blood, which was in turn less than that for red blood
cells. This meant that by whatever route the drug was
administered, higher concentrations were reached in
red blood cells and whole blood than in plasma, but
the concentrations declined at the same rate in the three
media thus giving similar half-lives. He also found that
the plasma, or whole blood or red blood cell, half-
lives varied depending upon whether the drug was
given orally, intramuscularly or intravenously. Plasma
chloroquine concentrations were determined using
High Performance Liquid Chromatography (HPLC)
method. Salako found that the plasma half-life of
chloroquine was significantly higher in renal
insufficiency patients than in controls. This finding
suggested that extra caution should be taken when
prescribing chloroquine for prolonged use in patients
with renal insufficiency. By this time, Prof  Salako had
become an internationally renowned Pharmacologist.
In 1989, a landmark paper was published by Prof
Salako and colleagues describing the Pharmacokinetics
of quinine in African children suffering from
kwashiorkor.19 They found that the apparent
absorption half-life of quinine was significantly longer
in kwashiorkor than in controls. In addition, they
discovered that the maximum concentration (Cmax)
of quinine was significantly lower in kwashiorkor than
in controls. Quinine was eliminated more slowly in
children with kwashiorkor with the elimination half-
life being significantly longer and the oral clearance
significantly less than in controls. It was concluded that
kwashiorkor significantly affects the pharmacokinetics
of quinine, and that the effect may be due to the
pathological changes in the intestine and liver in this
condition. In 1992, Salako and Sowunmi reported the
disposition of quinine in plasma, red blood cells and
saliva after oral and intravenous administration to
Prof. LA Salako
Prof Salako and colleagues published four significant
papers in 1979; one of them reported the
pharmacokinetics of  pindolol in 12 hypertensive
African subjects after a single oral dose of  the drug.8-
11 He found that the estimated pharmacokinetic
parameters did not differ significantly in Africans from
the values that had been observed in other races. In
the same group of papers published in 1979, he
described the comparative beta-adrenoreceptor-
blocking effects and pharmacokinetics or propranolol
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healthy adult Africans.20 They found that the half-lives
after the i.v. infusion did not differ from those after
oral administration. His studies of antimalarial therapies
are now classics; they initiated an era of superlative
malaria research that continues to thrive at the
department of  Pharmacology and Therapeutics,
University of  Ibadan, to this day. In 1994, Prof  Salako
and colleagues described an open, non-comparative
clinical trial that was carried out in Nigeria and Burkina
Faso to investigate the safety and efficacy of the novel
antimalarial arteflene in patients with mild malaria.21
This study showed that a single dose of 25 mg/kg
arteflene was found to be an effective and well-
tolerated treatment for mild P. falciparum malaria.
Conducting clinical trials is a major objective of the
department of  Clinical Pharmacology, University
College Hospital, Ibadan. The Department is one of
the Legacies of  Professor Lateef  Akinola Salako. His
career spanned through superlative animal and human
research on antihypertensives, clinical trials, and
malariology.
Other Notable Early Reports
Aderounmu, who was a collaborator with Professor
Salako, made significant contributions to clinical
pharmacokinetics. She did work on the
pharmacokinetics of  chloroquine which on their own
were landmark studies.22,23 Aderounmu reported that
different brands of chloroquine in Nigeria, at that time,
had similar bioavailability, although with some
variations in pharmaceutical properties. Those were
days when sub-standard products were rare or even
non-existent in Nigeria. Other early workers include
Ette and colleagues, who did major work on drug
interactions.24-28 Walker, who was in the same
department with Salako, evaluated the disposition of
chloroquine after oral and parenteral doses29, Essien30,
Adebayor and colleagues31-37, Ehiemua and colleagues38,
Brown-Awala and colleagues 39, Atawodi and
Maduagwu40, Goldzieher41, Ogbuokiri42, Onyeji43-48,
and Onyeyeli49, and their colleagues worked on
different aspects of  clinical pharmacokinetics.
This historical review is based on publications listed
on PUBMED and many other workers who made
significant contributions to clinical pharmacokinetics
in the early years of development of the field in Nigeria
may not have been listed here. The author
acknowledges this limitation. There is a need to
continue updating our records of great men and
women in the history of scientific research in our nation.
Evolving Relevance of  Clinical Pharmacokinetics
Further growth and development of clinical
pharmacokinetics will depend on vast improvements
in analytical methods and accompanying technologies.
Advances in engineering will significantly determine
the future utility of  clinical pharmacokinetics. A
miniature, non-invasive, remote, and cheap method
of monitoring drug concentrations is still being
developed. All advances will be centered on optimizing
patient care. Future advances will include developments
in the individualization of  therapy, in silico drug
screening and development, advances in sophisticated
computer programs with advances in super-
computing, defining biological constants that will
account for inter-individual variations in drug
concentration-time curves, pharmacokinetic-
pharmacogenetic inter-phases, development of  highly
specialized, multidisciplinary, pharmacokinetics
laboratories and therapeutic drug monitoring units, and
rapid response toxicology units.
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